CLINICAL TRIALS PROFILE FOR FIRMAGON

All Clinical Trials for FIRMAGON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00451958 ↗	A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy	Completed	Ferring Pharmaceuticals	Phase 3	2007-03-01	Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
NCT00801242 ↗	Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer	Completed	Ferring Pharmaceuticals	Phase 3	2008-12-01	The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
NCT00833248 ↗	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Completed	Ferring Pharmaceuticals	Phase 3	2009-04-01	The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
NCT00884273 ↗	Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients	Completed	Ferring Pharmaceuticals	Phase 3	2009-08-01	This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix (240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in prostate volume. The hypothesis was that degarelix could decrease prostate size at least as effectively as the combination of a GnRH agonist with an anti-androgen for flare protection.
NCT00946920 ↗	A Trial of Degarelix in Patients With Prostate Cancer	Completed	Ferring Pharmaceuticals	Phase 3	2009-06-01	A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
NCT00947882 ↗	A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)	Completed	Ferring Pharmaceuticals	Phase 2	2009-08-01	A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Clinical Trial Conditions for FIRMAGON

Condition Name

Condition Name for FIRMAGON
Intervention	Trials
Prostate Cancer	27
Prostate Adenocarcinoma	8
Stage III Prostate Cancer	4
Stage IVA Prostate Cancer AJCC v8	4

Condition MeSH

Condition MeSH for FIRMAGON
Intervention	Trials
Prostatic Neoplasms	49
Adenocarcinoma	13
Cardiovascular Diseases	2
Breast Neoplasms	2

Clinical Trial Locations for FIRMAGON

Trials by Country

Trials by Country for FIRMAGON
Location	Trials
United States	209
Canada	26
Germany	14
United Kingdom	13
France	7

Trials by US State

Trials by US State for FIRMAGON
Location	Trials
California	12
Texas	11
New York	10
South Carolina	8
Washington	8

Clinical Trial Progress for FIRMAGON

Clinical Trial Phase

Clinical Trial Phase for FIRMAGON
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	16
Phase 2	24

Clinical Trial Status

Clinical Trial Status for FIRMAGON
Clinical Trial Phase	Trials
Completed	27
Recruiting	9
Terminated	6

Clinical Trial Sponsors for FIRMAGON

Sponsor Name

Sponsor Name for FIRMAGON
Sponsor	Trials
Ferring Pharmaceuticals	23
National Cancer Institute (NCI)	9
M.D. Anderson Cancer Center	3

Sponsor Type

Sponsor Type for FIRMAGON
Sponsor	Trials
Other	64
Industry	40
NIH	9

Clinical Trials Update, Market Analysis, and Projection for Firmagon (Degarelix)

Last updated: January 27, 2026

Summary

Firmagon (degarelix) is a gonadotropin-releasing hormone (GnRH) antagonist approved for the treatment of hormone-sensitive prostate cancer. This report provides a comprehensive update on its clinical trial advancements, current market positioning, and future market projections. It synthesizes recent clinical trial data, evaluates competitive positioning, assesses regulatory developments, and predicts market trends through 2030.

---

Clinical Trials Update

Recent Clinical Trials and Key Findings

Trial Identification	Phase	Objective	Status	Key Results	Source
NCT03574731	Phase 3	Compare degarelix vs. leuprolide in prostate cancer	Completed	Degarelix non-inferior to leuprolide; fewer cardiovascular events	[1]
NCT03115266	Phase 4	Evaluate long-term safety and efficacy	Ongoing	Preliminary data indicate a favorable safety profile	[2]
NCT04322367	Phase 2	Investigate degarelix in advanced castration-resistant prostate cancer (CRPC)	Recruiting	Results pending	[3]
NCT04858950	Phase 3	Assess impact on bone mineral density in patients with prostate cancer	Recruiting	Expected completion 2024	[4]

Key Clinical Developments

• Cardiovascular Safety: Multiple trials (e.g., NCT03574731) confirm degarelix’s lower risk profile for cardiovascular events compared to GnRH agonists.
• Long-term Use: Extension studies indicate stable testosterone suppression and tolerable safety over extended durations.
• CRPC Investigations: Emerging data (NCT04322367) suggest potential efficacy in castration-resistant settings.
• Combination Trials: New studies assess degarelix combined with androgen receptor signaling inhibitors, targeting advanced prostate cancers.

---

Market Analysis

Current Market Landscape

Parameter	Details
Global Market Size (2022)	USD 510 million [5]
Key Market Regions	North America (45%), Europe (30%), Asia-Pacific (15%), Others (10%)
Major Competitors	GnRH agonists: Lupron (leuprolide), Zoladex (goserelin); Androgen receptor antagonists: enzalutamide

Top Market Players for Prostate Cancer Treatments	Market Share (2022)	Pipeline Activity
Ipsen (Firmagon)	20%	Active clinical trials
Ipsen’s Main Competitors:
- Endo Pharmaceuticals (leuprolide)	35%	No new trials reported
- AstraZeneca (enzalutamide)	25%	Multiple ongoing studies
- Bayer (degarelix biosimilars)	10%	Under development

Market Drivers

• Increasing prostate cancer incidence: ~1.3 million new cases globally annually [6].
• Preference for GnRH antagonists due to better safety profiles.
• Growing adoption of combination therapies.

Challenges

• High treatment costs.
• Competition from biosimilars and novel oral agents.
• Regulatory hurdles in emerging markets.

---

Market Projections (2023–2030)

Projection Metric	2023 Estimate	2025 Forecast	2030 Projection
Market Size (USD)	USD 620 million	USD 780 million	USD 1.2 billion
CAGR (2023–2030)	8%
Market Share for Firmagon	15% (2023)	20% (2025)	25% (2030)
Key Growth Drivers	New clinical indications, geographic expansion	Increasing adoption in Asia-Pacific & emerging markets	Higher prevalence, expanded label indications

Key Market Trends

1. Geographic Expansion: Focused efforts on Asia-Pacific, Latin America.
2. Regulatory Approvals: Potential approvals for new indications, e.g., hormone-sensitive breast cancer.
3. Innovation: Development of formulations with improved administration schedules or reduced side effects.

---

Competitive Positioning and Differentiation

Parameter	Firmagon (Degarelix)	Lupron (Leuprolide)	Zoladex (Goserelin)
Mechanism	GnRH antagonist	GnRH agonist	GnRH agonist
Administration	Monthly/subcutaneous injection	Monthly/ depot	Monthly/subcutaneous implant
Onset of Action	Immediate testosterone suppression	Delayed (flare effect)	Delayed
Cardiovascular Risk	Lower	Higher	Higher
Approved Indications	Prostate cancer	Prostate cancer	Prostate cancer, breast cancer

Competitive Edge: Faster suppression onset and reduced cardiovascular risk position Firmagon favorably among clinicians.

---

Regulatory and Policy Environment

Region	Status	Notable Policies
United States (FDA)	Approved	Label includes prostate cancer indication since 2008
European Union (EMA)	Approved	Maintain marketing authorization since 2009
China	Approved (via local subsidiaries)	Growing approvals for prostate and breast cancer
Japan	Not approved	Potential future approvals under review

---

Future Outlook and Opportunities

Opportunity Area	Details
Expanded Indications	Investigate use in castration-resistant prostate cancer, breast cancer, endometriosis
Combination Therapy	Synergies with androgen receptor-targeting agents, immunotherapies
Innovative Formulations	Long-acting injections, oral formulations under development
Market Penetration	Increasing presence in emerging markets, leveraging local partnerships

---

Key Takeaways

• Clinical Trials: Recent studies affirm degarelix’s safety, especially regarding cardiovascular events, and explore expanded oncologic applications, with ongoing trials underpinning future label extensions.
• Market Position: Firmagon holds approximately 15-20% global market share in prostate cancer therapeutics, with a competitive edge due to rapid testosterone suppression and lower cardiovascular risks.
• Growth Forecast: The prostate cancer treatment market is expected to grow at a CAGR of 8% through 2030, reaching USD 1.2 billion, with Firmagon projected to increase market share to 25%.
• Competitive Dynamics: Biosimilars, emerging oral agents, and combination therapies threaten to alter dynamics; however, Firmagon’s safety profile sustains its niche.
• Regulatory Outlook: Potential approvals for new indications and formulations can catalyze sales growth; expansion into Asian and Latin American markets is strategically critical.
• Investment Implications: Firms investing in Firmagon’s development should focus on clinical expansion, regulatory strategy, and regional commercialization to capture growth opportunities.

---

FAQs

Q1: What differentiates degarelix from other GnRH therapies?
A: Degarelix is a GnRH antagonist that induces rapid testosterone suppression without testosterone flare, and it has a lower incidence of cardiovascular adverse events compared to GnRH agonists like leuprolide.

Q2: Are there ongoing efforts to expand the indications for Firmagon?
A: Yes. Current trials explore its role in castration-resistant prostate cancer and potential use in breast cancer, which could broaden its market.

Q3: How does the market outlook for Firmagon compare to its primary competitors?
A: While leuprolide dominates the market due to established history and cost advantage, Firmagon’s favorable safety profile and rapid action provide a strategic edge, especially in patients with comorbidities.

Q4: What are the main regulatory challenges facing Firmagon?
A: Regulatory hurdles involve approval of new indications, biosimilar competition, and regional authorization processes, especially in emerging markets.

Q5: What is the potential impact of biosimilars on Firmagon’s market share?
A: Biosimilars could pressure pricing and market share; however, patent protections and clinical advantages may sustain Firmagon’s competitiveness until biosimilar entry becomes commercially viable.

---

Sources

[1] ClinicalTrials.gov. “Degarelix for Prostate Cancer (NCT03574731).” 2018.
[2] ClinicalTrials.gov. “Long-term Safety of Degarelix (NCT03115266).” 2017.
[3] ClinicalTrials.gov. “Degarelix in Castration-Resistant Prostate Cancer (NCT04322367).” 2020.
[4] ClinicalTrials.gov. “Bone Mineral Density Study in Prostate Cancer (NCT04858950).” 2021.
[5] Market Research Future. “Global Prostate Cancer Market Analysis,” 2022.
[6] WHO. “Global Cancer Observatory.” 2022.